After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...
Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...
After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback